Compare · LLY vs QTTB
LLY vs QTTB
Side-by-side comparison of Eli Lilly and Company (LLY) and Q32 Bio Inc. (QTTB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and QTTB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.09T, about 2459.8x QTTB ($442.7M).
- Over the past year, LLY is up 57.7% and QTTB is up 769.4% - QTTB leads by 711.7 points.
- LLY has been more active in the news (15 items in the past 4 weeks vs 4 for QTTB).
- LLY has more recent analyst coverage (25 ratings vs 14 for QTTB).
- Company
- Eli Lilly and Company
- Q32 Bio Inc.
- Price
- $1158.59-1.30%
- $14.91-0.67%
- Market cap
- $1.09T
- $442.7M
- 1M return
- +0.85%
- -4.82%
- 1Y return
- +57.67%
- +769.39%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 15
- 4
- Recent ratings
- 25
- 14
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LLY
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
- Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
- FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
- Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)
- Director Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)
- Director Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)
- EVP & President, LLY Int'l Jonsson Patrik sold $7,638,150 worth of shares (6,500 units at $1,175.10) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 54,147 units (SEC Form 4)
Latest QTTB
- CFO and President Kalowski Lee sold $65,776 worth of shares (3,972 units at $16.56), decreasing direct ownership by 3% to 138,471 units (SEC Form 4) (withholding obligation)
- CEO Morrison Jodie Pope sold $163,033 worth of shares (9,845 units at $16.56), decreasing direct ownership by 3% to 343,259 units (SEC Form 4) to satisfy tax liability
- Chief Scientific Officer Violette Shelia M. sold $46,335 worth of shares (2,798 units at $16.56), decreasing direct ownership by 2% to 127,771 units (SEC Form 4) (for tax liability)
- Morgan Stanley initiated coverage on Q32 Bio with a new price target
- SEC Form 10-Q filed by Q32 Bio Inc.
- Q32 Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Amendment: SEC Form SCHEDULE 13G/A filed by Q32 Bio Inc.
- SEC Form EFFECT filed by Q32 Bio Inc.
- SEC Form 424B3 filed by Q32 Bio Inc.